Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Total Debt (2016 - 2025)

Historic Total Debt for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to $37.0 million.

  • Coherus Oncology's Total Debt fell 1934.31% to $37.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year decrease of 1934.31%. This contributed to the annual value of $50.3 million for FY2024, which is 7985.52% down from last year.
  • Per Coherus Oncology's latest filing, its Total Debt stood at $37.0 million for Q3 2025, which was down 1934.31% from $36.9 million recorded in Q2 2025.
  • Coherus Oncology's Total Debt's 5-year high stood at $250.3 million during Q3 2023, with a 5-year trough of $36.9 million in Q2 2025.
  • Moreover, its 5-year median value for Total Debt was $75.2 million (2021), whereas its average is $133.0 million.
  • In the last 5 years, Coherus Oncology's Total Debt skyrocketed by 22598.63% in 2022 and then tumbled by 8169.08% in 2024.
  • Over the past 5 years, Coherus Oncology's Total Debt (Quarter) stood at $75.5 million in 2021, then surged by 225.09% to $245.5 million in 2022, then rose by 1.75% to $249.8 million in 2023, then plummeted by 79.86% to $50.3 million in 2024, then decreased by 26.55% to $37.0 million in 2025.
  • Its Total Debt was $37.0 million in Q3 2025, compared to $36.9 million in Q2 2025 and $63.0 million in Q1 2025.